Predavanje (9. srpnja)
U predavaonici Instituta u ponedjeljak 9.7.2018. u 14:00 sati održat će se predavanje prof. dr. sc. Eve Roblegg s Instituta za farmaciju Sveučilišta u Grazu.
Naslov predavanja je Impact of oral biological barriers on the fate of nanoparticles in the oral cavity: translation into drug delivery
Sažetak predavanja
The oral cavity, often referred as the mirror of the body, is a well-organized system that reflects and supports human health. It communicates with the external environment and fosters characteristic microorganisms. Further functions include protection, to withstand mechanical forces and prevent uptake of foreign substances, sensory perception, and secretion of saliva. Disruptions in the homoeostasis increase the risk of oral diseases. Major risk factors include physical factors, immune-mediated and metabolic diseases, chemical substances and microbial infections [1]. A possible way of improving treatment of oral diseases above current standard of care is the development of drug delivery systems that can be applied locally. Thereby, the use of nano-carriers has proven advantageous at solubilizing drugs, protecting them from enzymatic degradation and prolonging their residence time. However, the rational design of such systems is still challenging, because of lack of understanding of the biological processes governing the main barriers that nanoparticles encounter during administration.
The talk will elucidate the main biological barriers taking into consideration physiological changes due to inflammation. The talk will also demonstrate how physico-chemical nanoparticle properties, such as size, surface functionalization and hydrophilicity affect colloidal stability, mobility and consequently, cellular uptake and penetration into deeper tissue [2]. Moreover, examples of therapeutic nanoparticles will be discussed [3].
- Federation, F. W. D. The challenge of oral diseases- a call for global action (FDI World Dental Federation) 2015.
- Teubl, B.J. et al.: Clinical Oral Investigations. 2018, 22(2):929-940.
- Tetyczka, C. et al., Int J Pharm. 2017, 526(1-2):188-198.
Kratki životopis predavača
Assoc. Prof. Dr. Eva Roblegg is pharmaceutical scientist at the Institute of Pharmaceutical Sciences, Deputy Head of the Department Pharmaceutical Technology and Biopharmacy at the Karl-Franzens University, Graz, Austria (http://www.uni-graz.at) and key researcher at the Research Center Pharmaceutical Engineering (http://www.rcpe.at/). After a research visit at the Johann Wolfgang Goethe-University (Frankfurt, Germany) she finished her PhD in 2000. She took a maternity leave, spent two years in pharmacy and was approbated as pharmacist in 2005. In 2006, she joined the Institute of Pharmaceutical Sciences, Department of Pharmaceutical Technology and Biopharmacy in Graz as post-doctoral fellow and later on as Assistant Professor. In 2012 she spent 8 months as guest scientist at the Saarland University, Department Biopharmaceutics and Pharmaceutical Technology and at the Helmholtz Institute for Pharmaceutical Research Saarland, Drug Delivery Department (Saarbrücken, Germany) and was awarded with the Galenus Technology Prize 2013. She finished her habilitation in May 2014; in 2015 and 2018 she held Guest Professorships at the University of Ljubiljana, Slovenia and at Standford University, USA. The main focus of her research are biological barriers, in particular the oral cavity and the small intestine. In parallel, she is interested in finding oral multifunctional (nano-) drug delivery systems and developing advanced manufacturing methods such as (nano)extrusion and (nano)printing. She has (co-) supervised more than 30 diploma theses, 5 PhD students and 2 PostDocs and her publication record encompasses over 60 peer-reviewed publications and several book chapters (h-index 18). She holds two patents in the area of pharmaceutical manufacturing and has received grant support from e.g., Austrian Research Promotion Agency (FFG), EU, OECD and several industry partners.
Currently, she is Head of the Doctoral School of Pharmaceutical Sciences and Member of the Curricula Committee. Since 2009 she is also OECD Member of the Steering Group 7 for Alternative Testing Models. She serves on the editorial board of NanoTexLetters and acts as reviewer for journals such as, Nature Communications, Small, EJPB, IJP, DDIP, CLOI, Particle and Fiber Tox, Nanomedicine: Nanotechnology, Biology, and Medicine, etc..